NewsBenzinga비바니 메디컬, 2027년 2상 임상시험을 목표로 장기지속형 세마글루타이드 이식제 개발 진행 비바니 메디컬, 2027년 2상 임상시험을 목표로 장기지속형 세마글루타이드 이식제 개발 진행 Benzinga 2026.11.12 17:08 (GMT+0) Open on Benzinga Other news Snowflake-Led AI Group Wins US Export Program Backing Solflare CEO: AI Security Reviews Being Built Into Development Pipeline, MoneyGram Integration Enables USDC-to-Cash Redemption Lighter Security Incident Update: About 5 Million USDC Returned to Affected Users, Withdrawals Resumed Supply Chain Attack on Optimizely Affects at Least 186 Websites, Aimed at Stealing Crypto Assets and Payment Info Jana Partners Cashes Out of One Data Center Stock for Another and Buys Trash Company Stock in Q3 Seth Klarman’s Baupost Group Takes New Position in Honeywell Aerospace in Q3
Solflare CEO: AI Security Reviews Being Built Into Development Pipeline, MoneyGram Integration Enables USDC-to-Cash Redemption
Lighter Security Incident Update: About 5 Million USDC Returned to Affected Users, Withdrawals Resumed
Supply Chain Attack on Optimizely Affects at Least 186 Websites, Aimed at Stealing Crypto Assets and Payment Info